Cullinan Therapeutics, Inc. (CGEM) Financial Ratios
8 years of historical data (2018–2025) · Healthcare · Medical - Pharmaceuticals
EV/EBITDA
N/A
—
5yr avg: 2.36
30Y Low2.4·High2.4
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
2.17
↑+79% vs avg
5yr avg: 1.21
30Y Low0.9·High1.6
ROE
↓
-44.0%
↑-110% vs avg
5yr avg: -21.0%
30Y Low-65%·High23%
Debt/EBITDA
N/A
—
5yr avg: 0.04
30Y Low0.0·High0.0
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
CGEM Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Cullinan Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $903M | $611M | $655M | $423M | $492M | $683M | — | — | — |
| Enterprise Value | $817M | $526M | $574M | $329M | $341M | $624M | — | — | — |
| P/E Ratio → | -4.03 | — | — | — | 4.43 | — | — | — | — |
| P/S Ratio | — | — | — | — | — | 36.08 | — | — | — |
| P/B Ratio | 2.17 | 1.50 | 1.11 | 0.93 | 0.92 | 1.61 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
CGEM EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | 32.92 | — | — | — |
| EV / EBITDA | — | — | — | — | 2.36 | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
CGEM Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -44.0% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | 100.0% | — | — | — |
| Operating Margin | — | — | — | — | — | -358.7% | — | — | — |
| Net Profit Margin | — | — | — | — | — | -346.1% | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -44.0% | -44.0% | -32.1% | -31.0% | 23.2% | -21.0% | -64.6% | — | — |
| ROA | -41.1% | -41.1% | -30.3% | -29.3% | 22.3% | -20.1% | -32.9% | -29.7% | -41.0% |
| ROIC | -43.5% | -43.5% | -34.0% | -38.6% | 28.9% | -25.6% | — | — | — |
| ROCE | -48.2% | -48.2% | -37.6% | -38.4% | 30.0% | -21.7% | -40.4% | -33.9% | -43.8% |
CGEM Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $88M exceeds total debt of $3M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.00 | 0.01 | 0.01 | — | — | — | — |
| Debt / EBITDA | — | — | — | — | 0.04 | — | — | — | — |
| Net Debt / Equity | — | -0.21 | -0.14 | -0.21 | -0.28 | -0.14 | -0.84 | — | — |
| Net Debt / EBITDA | — | — | — | — | -1.04 | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — |
Net cash position: cash ($88M) exceeds total debt ($3M)
CGEM Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Cullinan Therapeutics, Inc.'s current ratio of 10.25x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 17.07x to 10.25x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.25 | 10.25 | 13.53 | 17.07 | 21.09 | 25.25 | 14.82 | 39.67 | 25.85 |
| Quick Ratio | 10.25 | 10.25 | 13.53 | 17.07 | 21.09 | 25.25 | 14.82 | 39.67 | 25.85 |
| Cash Ratio | 10.01 | 10.01 | 13.02 | 16.60 | 20.77 | 24.73 | 14.68 | 39.09 | 25.55 |
| Asset Turnover | — | — | — | — | — | 0.04 | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — |
CGEM Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Cullinan Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | 22.6% | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $59M | $54M | $42M | $47M | $44M | $44M | $1M | $800038 |
Peer Comparison
Compare CGEM with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 CGEMYou | $903M | -4.0 | — | — | — | — | -44.0% | -43.5% | — |
 IMVT | $6B | -10.5 | — | — | — | — | -62.5% | — | — |
 KYMR | $7B | -23.4 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 RCUS | $3B | -7.9 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 PRCT | $1B | -14.4 | — | — | 63.7% | -33.7% | -24.9% | -55.7% | — |
 TPST | $56M | -1.3 | — | — | — | — | -182.3% | -507.5% | — |
 AGEN | $137M | -1144.1 | — | — | 90.3% | -18.0% | — | — | — |
 NKTR | $2B | -8.7 | — | — | — | -253.7% | -217.9% | -75.2% | — |
 ALNY | $40B | 130.0 | 71.9 | 86.9 | 81.8% | 13.5% | 73.3% | 33.4% | 2.3 |
 FATE | $264M | -2.0 | — | — | — | -2222.4% | -51.8% | -36.5% | — |
 BEAM | $3B | -39.9 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 8 years · Updated daily
See CGEM's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CGEM Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CGEM vs IMVT
Side-by-side business, growth, and profitability comparison vs Immunovant, Inc..
Start ComparisonCGEM — Frequently Asked Questions
Quick answers to the most common questions about buying CGEM stock.
What is Cullinan Therapeutics, Inc.'s P/E ratio?
Cullinan Therapeutics, Inc.'s current P/E ratio is -4.0x. The historical average is 4.4x.
What is Cullinan Therapeutics, Inc.'s ROE?
Cullinan Therapeutics, Inc.'s return on equity (ROE) is -44.0%. The historical average is -28.2%.
Is CGEM stock overvalued?
Based on historical data, Cullinan Therapeutics, Inc. is trading at a P/E of -4.0x. Compare with industry peers and growth rates for a complete picture.